Reverse Phase HPLC Determination of Azq in Biological Fluids

References

• Khan , A. H. and Driscoll , J. S. 1976 . Potential Central Nervous System Antitumor Agents. Aziridinylbenzoquinones. 1 . J. Med. Chem. , 19 : 313
   PubMed Web of Science ®Google Scholar
• Chou , F. , Khan , A. H. and Driscoll , J. S. 1976 . Potential Central Nervous System Antitumor Agents. Aziridinylbenzoquinones. 2 . J. Med. Chem. , 19 : 1302
   PubMed Web of Science ®Google Scholar
• Driscoll , J. S. , Dudeck , L. , Congleton , G. and Geran , R. I. 1979 . Potential CNS Antitumor Agents VI: Aziridinylbenzoquinones III . J. Pharm. Sci. , 68 : 185
   PubMed Web of Science ®Google Scholar
• Poochikian , G. K. and Kelley , J. A. 1981 . 2,5‐Diaziridinyl‐3,6‐bis‐(carboethoxyamino)‐1,4‐benzoquinone II: Isolation and Characterization of Degradation Products . J. Pharm. Sci. , 70 : 162
   PubMed Web of Science ®Google Scholar
• Poochikian , G. K. and Cradock , J. C. 1981 . 2,5‐Diaziridinyl‐3,6‐bis(carboethoxyamino)‐1,4‐benzoquinone I: Kinetics in Aqueous Solutions by High‐Performance Liquid Chromatography . J. Pharm. Sci. , 70 : 159
   PubMed Web of Science ®Google Scholar
• Gibaldi , M. and Perrier , D. 1975 . Pharmacokinetics , New York : Marcel Dekker .
   Google Scholar
• Sui Chong , E. S. unpublished results
   Google Scholar
• DADCQ was the major synthetic impurity (1.5% w/w) in early batches of AZQ. This contaminant was not present in the later batches used in the clinical formulation because of a slightly different method of synthesis
   Google Scholar
• Gormley , P. E. , Wood , J. and Poplack , D. G. 1981 . Ability of a New Antitumor Agent, AZQ, to Penetrate into CSF . Pharmacology , 22 : 196
   Google Scholar